(MENAFN - ProactiveInvestors - Australia) Bluechiip (ASX: BCT) has executed a licensing deal with U.S.-based technology manufacturer MiTeGen for Bluechiip's tracking technology to be used in the tracking of cryopins.
Cryopins, the common name for crystallography goniometer bases for crystal mounts, are used in synchrotrons
Importantly, the deal adds a further product to Bluechiip's product range and another revenue stream as the company moves into the commercialisation phase.
The cryopin global market is estimated to use 2 million per year in synchrotrons across the world, with other uses in markets including research and science which are yet to be explored.
MiTeGen is one of the world's major suppliers of cryopins.
The agreement with Bluechiip allows MiTeGen to integrate Bluechiip's tracking technology into the cryopins it manufactures and sell to Australian Synchrotron, for which Bluechiip has just completed a project, as well as other synchrotrons around the world.
MiTeGen designs, manufactures and distributes products for crystallisation, crystallography and x-ray diffraction of proteins, viruses and small molecule/inorganic compounds.
Bluechiip has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries.
The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags.
Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items.
The bluechiip technology offers numerous advantages over traditional bar-coding of bases and is extremely well suited for cryogenic conditions, as well as room temperature studies.